NCT05407220View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

July 25, 2022

Study Completion Date

July 25, 2022

Conditions
Healthy
Interventions
DRUG

HCP1904-1

take it once per period

DRUG

HCP1904-3

take it once per period

Trial Locations (1)

Unknown

Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT05407220 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers. | Biotech Hunter | Biotech Hunter